Integer price target raised to $145 from $137 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Integer to $145 from $137 and keeps a Buy rating on the shares. The company has reached an agreement to sell its Electrochem franchise for $50M, shifting its business to a faster-growing and more profitable profile while becoming a higher growth and margin pureplay supplier/manufacturer for the MedTech industry, the analyst tells investors in a research note. Truist adds that Integer has “scarcity value” as a profitable SMID with a ‘steady-eddy’ growth and profile.